VBI Vaccines, Inc. – (NASDAQ:VBIV) shares saw unusually-high trading volume on Thursday . Approximately 231,194 shares changed hands during mid-day trading, an increase of 136% from the previous session’s volume of 98,079 shares.The stock last traded at $3.75 and had previously closed at $3.66.

Separately, Ladenburg Thalmann assumed coverage on VBI Vaccines, Inc. – in a report on Tuesday, July 26th. They issued a “buy” rating on the stock.

The firm’s 50-day moving average price is $3.78 and its 200-day moving average price is $3.92. The company’s market cap is $118.03 million.

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.